According to The Insight Partners research, the global Leukapheresis Market is slated to be worth US$ 133.90 million by 2028 from US$ 74.48 million in 2021, expanding at 8.7% CAGR from 2021 to 2028. Rising number of voluntary blood donors, increasing incidence of hematologic diseases, and surging geriatric populace are the crucial factors credited for this expansion.

Blood transfusion is an integral part of the national health infrastructure and policies of various countries. Advancements in the medical industry have led to improvements in the treatment procedures of serious illnesses and injuries, which has eventually propelled the need for blood transfusion for patients’ survival. Growing awareness regarding the importance of blood transfusion and blood availability in healthcare services has led to rise in the number of people willing to donate their blood for medical causes, in turn, aiding market augmentation.

Blood diseases disturb the overall well-being of patients. Anemia; hemophilia; von Willebrand disease (VWD); blood cancers such as myeloma, leukemia, and lymphoma are among the common blood diseases. The number of newly diagnosed leukemia cases increased from 354,500 in 1990 to 518,500 in 2017. The rising incidence of these diseases maximizes the need for blood transfusion, thereby bolstering the demand for leukapheresis equipment. On the other hand, the high cost of leukapheresis will likely hinder market augmentation over the forecast timeframe.

Based on product type, the market is bifurcated into leukapheresis disposables and leukapheresis devices. Among these, the leukapheresis disposables segment held 61.43% of the market share in 2021. The segment was gauged at US$ 45.75 million in 2021 and is projected to garner US$ 80.29 million by 2028, growing at 8.4% CAGR during 2021–2028.

As per application scope, the leukapheresis market is split into research and therapeutic applications. Of these, the research segment captured 63.52% of the market share in 2021. The segment was appraised at US$ 47.31 million in 2021 and is predicted to accrue US$ 86.75 million by 2028, expanding at 9.0% CAGR from 2021 to 2028.